The CLAIMS consortium convened its 4th General Assembly (GA) on November 12, 2025, in the scenic town of Baveno, Italy. The event was a hybrid meeting, combining the face-to-face gathering in Baveno with online attendance, bringing together partners united by one mission: accelerating AI-enabled innovations for multiple sclerosis (MS) care. The meeting included dynamic updates on project progress and key administrative milestones.
RECLAIM: countdown to dataset finalisation
Partners exchanged insights on the remarkable advancements of the RECLAIM study, the project’s retrospective clinical trial.
The study now includes longitudinal data from more than 7,500 patients and over 55,000 quantitatively analyzed MRI scans. Additionally, the consortium has collected longitudinal datasets of optical coherence tomography (OCT) and visual evoked potential (VEP) measurements from patient subsets. With the data collection deadline approaching in mid-December 2025, the partners are making a final push to complete and harmonise the dataset.
All patient-level data collected were systematically linked and mapped into an MS-specific Common Data Model (CDM). This CDM was developed collaboratively across the CLAIMS consortium to handle the real-world complexity and variety of clinical datasets. The consortium is currently preparing a manuscript to describe the structure of the CDM in detail and make it available to the wider research community.
Cohort update
Analysed MRI scans
0
Patients (retrospective cohort)
0
CDM
MS-specific
AI models: requirements and clinical impact in prognostic decision support
The participants engaged in a productive discussion on how the RECLAIM dataset is being used to develop prognostic AI models that are technically feasible and clinically useful. The focus of this work is on developing models for patient specific treatment recommendations. Such models include:
- A biomarker based multiple sclerosis progression model describing the joint evolution of biomarkers along the disease trajectory.
- An MRI focused generative model to predict longitudinal structural brain changes.
- A computational tool for therapy escalation, to assist clinicians in deciding whether to switch a patient from a low to a higher efficacy disease modifying treatment (DMT).
The meeting included an active brainstorming session to define user requirements for the assistive predictive modelling software. Key discussion points included establishing relevant time horizons, specifically how much historical data models should learn from and how far into the future they should predict disease progression.
PROCLAIM: prospective evaluation of AI-assisted MS care
A key highlight of the GA was the update on the PROCLAIM study, the consortium’s prospective clinical trial. This study is designed to evaluate the real-world impact of CLAIMS AI tools in MS care, including quantitative biomarkers of inflammatory and smouldering disease activity.
The randomised study aims to enrol 750 patients, comparing a control arm (Standard of Care) to an intervention arm (Standard of Care plus icobrain mr quantitative imaging results).
The consortium aligned on the next steps for site initiation and patient recruitment, ensuring the study is progressing according to plan.
Engaging with the wider MS community
Following the GA, several CLAIMS partners actively participated in the European Charcot Foundation (ECF) Annual Meeting, attending invited talks and engaging with the broader MS research community. Consortium members also took part in the MS Initiatives meeting organised by the ECF, where they exchanged perspectives with other major MS initiatives.
These interactions created valuable opportunities for scientific discussion, knowledge exchange, and alignment with complementary European efforts in MS research. The insights gained are expected to further strengthen the communication, dissemination, and impact strategy of the CLAIMS project.
In addition, project representatives Diana Sima and Vincenzo Anania (icometrix), and Prof. Friedemann Paul (Charité – Universitätsmedizin Berlin, academic coordinator) recorded interviews to share their perspectives on how and why the project was initiated and the road ahead. The conversation explored the project’s overarching mission and what makes it unique, the importance of AI-assisted MS care and multidisciplinary collaboration, and how CLAIMS may shape the future of neurological research. Stay tuned for the full video!
